Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update (2025)

1.1 Summary of changes
1.2 PsO market to experience conservative growth from 2020-30
1.3 New players to enter a saturated field
1.4 Opportunities remain for undertreated patient populations
1.5 Innovator small molecules dominate the late-stage pipeline
1.6 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods.
4.5 Epidemiological forecast for PsO (2020-30)
4.5.1 Lifetime diagnosed prevalent cases of PsO
4.5.2 Age-specific lifetime diagnosed prevalent cases of PsO
4.5.3 Sex-specific lifetime diagnosed prevalent cases of PsO
4.5.4 Lifetime diagnosed prevalent cases of PsO by severity in the adult population
4.5.5 Lifetime diagnosed prevalent cases of PsO with PsA in the adult population
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of analysis
4.6.4 Strengths of analysis

5.1 Diagnosis
5.2 Treatment

6.1 Overview
6.1.1 TNF inhibitors
6.1.2 IL-17 inhibitors
6.1.3 IL-12/23 inhibitors and IL-23 inhibitors
6.1.4 PDE4 inhibitors
6.1.5 Kinase inhibitors
6.1.6 Other disease modifying therapies
6.2 Biosimilars

7.1 Overview
7.2 Cost-effective therapies
7.3 Efficacious therapies for treatment refractory patients
7.4 Lack of innovative topical therapies
7.5 Treatment options for mild PsO patients

8.1 Development shifts away from injectable biologics
8.2 New players enter the late-stage pipeline
8.3 Clinical trials design
8.3.1 Robust clinical endpoints
8.3.2 Long-term patient follow-up
8.3.3 Active comparator trials

9.1 Overview
9.2 Promising drugs in clinical development
9.2.1 Sonelokimab
9.2.2 Icotrokinra
9.2.3 TAK-279
9.2.4 Orismilast
9.2.5 Piclidenoson
9.3 Other drugs of note
9.3.1 Balinatunfib (SAR441566)
9.3.2 DC-806
9.3.3 Mirikizumab
9.3.4 Brepocitinib tosylate

10.1 Overview
10.2 Competitive assessment
10.2.1 Biologic medications
10.2.2 Small molecule therapeutics

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Abbreviations
13.2 Methodology
13.2.1 Forecasting methodology
13.3 Primary research - KOLs and payors interviewed for this report
13.3.1 KOLs
13.3.2 Payers
13.4 Bibliography
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Epidemiologist
13.6.4 Reviewers
13.6.5 Vice President of Disease Intelligence and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy

• About the Analyst
• Contact the Publisher

Table 1: Plaque psoriasis: key metrics in the 7MM
Table 2: Summary of changes to PsO: Seven-Market Drug Forecast and Analysis Report
Table 3: Risk factors and comorbidities for PsO
Table 4: Classification of PsO by BSA
Table 5: Treatment guidelines for plaque psoriasis
Table 6: Top completed deals in PsO market by value, 2018-23
Table 7: PsO market - global drivers and barriers, 2020-30
Table 8: Key events impacting sales for PsO in the US, 2020-30
Table 9: PsO market - drivers and barriers in the US, 2020-30
Table 10: Key events impacting sales for PsO in the 5EU, 2020-30
Table 11: PsO market - drivers and barriers in the 5EU, 2020-30
Table 12: Key events impacting sales for PsO in Japan, 2020-30
Table 13: PsO market - drivers and barriers in Japan, 2020-30
Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for PsO in 2020 and 2030
Figure 2: Analysis of the company portfolio gap in PsO during the forecast period
Figure 3: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
Figure 4: Competitive assessment of the pipeline small molecule drugs benchmarked against the SOC, Otezla
Figure 5: Biologic and small molecule targets in the treatment of PsO
Figure 6: 7MM, lifetime diagnosed prevalence of pediatric PsO (%), boys and girls, ages =17 years, 2020
Figure 7: 7MM, lifetime diagnosed prevalence of adult PsO (%), men and women, ages =18 years, 2020
Figure 8: Sources used for lifetime diagnosed prevalent cases of pediatric PsO
Figure 9: Sources used and not used for lifetime diagnosed prevalent cases of PsO in adults
Figure 10: Sources used for lifetime diagnosed prevalent cases of PsO by severity among adults
Figure 11: Sources used for lifetime diagnosed prevalent cases of PsO with PsA among adults
Figure 12: 7MM, lifetime diagnosed prevalent cases of PsO, men and women, all ages, 2020 (N)
Figure 13: Age-specific lifetime diagnosed prevalent cases of PsO, 7MM, men and women, 2020 (N)
Figure 14: 7MM, sex-specific lifetime diagnosed prevalent cases of PsO, all ages, 2020 (N)
Figure 15: 7MM, lifetime diagnosed prevalent cases of PsO by severity, men and women, =18 years, 2020
Figure 16: 7MM, lifetime diagnosed prevalent cases of PsO with psoriatic arthritis, men and women, =18 years, 2020 (N)
Figure 17: Overall treatment algorithm for PsO as approved by the EMA
Figure 18: Unmet needs and opportunities in PsO
Figure 19: Overview of the development pipeline in PsO
Figure 20: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for PsO in the 7MM during the forecast period
Figure 21: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
Figure 22: Competitive assessment of the pipeline small molecules drugs benchmarked against the SOC, Otezla
Figure 23: Analysis of the company portfolio gap in PsO during the forecast period
Figure 24: Global (7MM) sales forecast by country for PsO in 2020 and 2030
Figure 25: Sales forecast by class for PsO in the US in 2020 and 2030
Figure 26: Sales forecast by class for PsO in the 5EU in 2020 and 2030
Figure 27: Sales forecast by class for PsO in Japan in 2020 and 2030